(untitled) - Sridhar, S S; Mackenzie, M J; Hotte, S J (Invest New Drugs, 2013)
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium